TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Role of Coumadin in Preventing Periprocedural Thrombo-Embolism as a Complication of Radio Frequency Catheter Ablation in High-risk Atrial Fibrillation Patients
Brief Summary: This study aims to explore the risk of periprocedural thromboembolic events in continuous versus interrupted Coumadin therapy in a large, randomized high-risk patient population undergoing radio-frequency catheter ablation for atrial fibrillation.


Options:
A: Arm Label: Interrupted apixaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interrupted apixaban | Arm Label: Uninterrupted apixaban; Type: EXPERIMENTAL; Interventions: Drug: Uninterrupted apixaban | Intervention Type: DRUG; Name: Interrupted apixaban; Assigned to Arm(s): Interrupted apixaban | Intervention Type: DRUG; Name: Uninterrupted apixaban; Assigned to Arm(s): Uninterrupted apixaban
B: Arm Label: Standard medical therapy group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Catheter ablation group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Catheter ablation | Intervention Type: PROCEDURE; Name: Catheter ablation; Assigned to Arm(s): Catheter ablation group
C: Arm Label: Continuous heparin infusion group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Continuous heparin infusion | Arm Label: Intermittent heparin infusion group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent heparin infusion | Intervention Type: DRUG; Name: Continuous heparin infusion; Assigned to Arm(s): Continuous heparin infusion group | Intervention Type: DRUG; Name: Intermittent heparin infusion; Assigned to Arm(s): Intermittent heparin infusion group
D: Arm Label: Study Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coumadin | Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Coumadin | Intervention Type: DRUG; Name: Coumadin; Assigned to Arm(s): Study Arm | Intervention Type: DRUG; Name: Coumadin; Assigned to Arm(s): Control Arm | Intervention Type: DRUG; Name: Coumadin; Assigned to Arm(s): Control Arm, Study Arm

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Micro Dose Gonadotropin-Releasing Hormone (GnRH) Agonist Flare up & Flare Protocol in Poor Responders in Assisted Reproductive Technology (ART) Cycle
Brief Summary: About 9 to 24 % of women undergoing in vitro fertilization (IVF) treatment respond poorly to the usual gonadotrophin stimulation protocol applied. Several induction ovulation treatments have been suggested for increasing pregnancy rate. In this study, the investigators will compare the outcome of Microflare protocol and Flare up regimen in poor responders.


Options:
A: Arm Label: 450 IU daily dose of gonadotrophin; Type: ACTIVE_COMPARATOR; Interventions: Drug: menotropins for injection, Drug: urofollitropin for injection | Arm Label: 600 IU daily dose of gonadotrophin; Type: EXPERIMENTAL; Interventions: Drug: menotropins for injection, Drug: urofollitropin for injection | Intervention Type: DRUG; Name: menotropins for injection; Assigned to Arm(s): 450 IU daily dose of gonadotrophin, 600 IU daily dose of gonadotrophin | Intervention Type: DRUG; Name: urofollitropin for injection; Assigned to Arm(s): 450 IU daily dose of gonadotrophin, 600 IU daily dose of gonadotrophin
B: Arm Label: Flare Up; Type: ACTIVE_COMPARATOR; Interventions: Drug: Flare up | Arm Label: Microdose GnRh; Type: EXPERIMENTAL; Interventions: Drug: Microdose GnRh | Intervention Type: DRUG; Name: Microdose GnRh; Assigned to Arm(s): Microdose GnRh | Intervention Type: DRUG; Name: Flare up; Assigned to Arm(s): Flare Up
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Follitropin Delta (FE 999049) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin Alfa (GONAL-F) | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Follitropin Delta (FE 999049) | Arm Label: D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin Alfa (GONAL-F) | Intervention Type: DRUG; Name: Follitropin Delta (FE 999049); Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Follitropin Alfa (GONAL-F); Assigned to Arm(s): B, D
D: Arm Label: "Individual" or "standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: rFSH drug dose | Arm Label: "Standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: "Standard" rFSH dose | Intervention Type: DRUG; Name: rFSH drug dose; Assigned to Arm(s): "Individual" or "standard" rFSH dose | Intervention Type: DRUG; Name: "Standard" rFSH dose; Assigned to Arm(s): "Standard" rFSH dose

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized ActiveStep Comparative Effectiveness Trial
Brief Summary: The investigators are conducting a multi-center randomized prospective trial comparing a standard physical therapy gait and balance program with a gait and balance program that includes the ActiveStep™ treadmill.

Subjects will be randomized to either have the ActiveStep™ as part of their therapy or to have their therapy without it. Data will be gathered from session notes, medical records and short interviews with the subjects at baseline and every 3 months over the telephone for the duration of the study.


Options:
A: Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Behavioral: No Intervention | Arm Label: Vigorous Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Vigorous Exercise | Arm Label: Moderate Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Moderate Exercise | Intervention Type: BEHAVIORAL; Name: Moderate Exercise; Assigned to Arm(s): Moderate Exercise | Intervention Type: BEHAVIORAL; Name: Vigorous Exercise; Assigned to Arm(s): Vigorous Exercise | Intervention Type: BEHAVIORAL; Name: No Intervention; Assigned to Arm(s): Control Group
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Azilect®; Type: EXPERIMENTAL; Interventions: Drug: Azilect® | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Azilect®; Assigned to Arm(s): Azilect®
C: Arm Label: CVT-301 Low Dose; Type: EXPERIMENTAL; Interventions: Drug: CVT-301 Low Dose | Arm Label: CVT-301 High Dose; Type: EXPERIMENTAL; Interventions: Drug: CVT-301 High Dose | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CVT-301 Low Dose; Assigned to Arm(s): CVT-301 Low Dose | Intervention Type: DRUG; Name: CVT-301 High Dose; Assigned to Arm(s): CVT-301 High Dose | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: ActiveStep; Type: ACTIVE_COMPARATOR; Interventions: Device: ActiveStep Treadmill | Arm Label: Standard physical therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical Therapy | Intervention Type: DEVICE; Name: ActiveStep Treadmill; Assigned to Arm(s): ActiveStep | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): Standard physical therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized ActiveStep Comparative Effectiveness Trial
Brief Summary: The investigators are conducting a multi-center randomized prospective trial comparing a standard physical therapy gait and balance program with a gait and balance program that includes the ActiveStep™ treadmill.

Subjects will be randomized to either have the ActiveStep™ as part of their therapy or to have their therapy without it. Data will be gathered from session notes, medical records and short interviews with the subjects at baseline and every 3 months over the telephone for the duration of the study.


Options:
A: Arm Label: TT+VR; Type: EXPERIMENTAL; Interventions: Other: TT+VR | Arm Label: TT alone; Type: ACTIVE_COMPARATOR; Interventions: Other: TT alone | Intervention Type: OTHER; Name: TT+VR; Assigned to Arm(s): TT+VR | Intervention Type: OTHER; Name: TT alone; Assigned to Arm(s): TT alone
B: Arm Label: Nutritional Intervention; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Nutritional Intervention | Arm Label: Physical Exercise; Type: EXPERIMENTAL; Interventions: Other: Physical Exercise | Arm Label: Cognitive Training; Type: EXPERIMENTAL; Interventions: Other: Cognitive Training | Arm Label: Combined; Type: EXPERIMENTAL; Interventions: Other: Combined | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutritional Intervention; Assigned to Arm(s): Nutritional Intervention | Intervention Type: OTHER; Name: Physical Exercise; Assigned to Arm(s): Physical Exercise | Intervention Type: OTHER; Name: Cognitive Training; Assigned to Arm(s): Cognitive Training | Intervention Type: OTHER; Name: Combined; Assigned to Arm(s): Combined | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Control Group
C: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: physical therapy | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: physical therapy; Assigned to Arm(s): Intervention Group
D: Arm Label: ActiveStep; Type: ACTIVE_COMPARATOR; Interventions: Device: ActiveStep Treadmill | Arm Label: Standard physical therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Physical Therapy | Intervention Type: DEVICE; Name: ActiveStep Treadmill; Assigned to Arm(s): ActiveStep | Intervention Type: OTHER; Name: Physical Therapy; Assigned to Arm(s): Standard physical therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BRIM 3: A Randomized, Open-Label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving Vemurafenib (RO5185426) or Dacarbazine
Brief Summary: This randomized, open-label study evaluated the efficacy, safety and tolerability of vemurafenib (RO5185426) as compared to dacarbazine in previously untreated patients with metastatic melanoma. Patients were randomized to receive either vemurafenib 960 mg orally twice daily or dacarbazine 1000 mg/m2 intravenously every 3 weeks. Study treatment was continued until disease progression or unacceptable toxicity occurred. The data and safety monitoring board recommended that patients in the dacarbazine group be allowed to cross over to receive vemurafenib, and the protocol was amended accordingly on January 14, 2011, as both overall survival and progression-free survival endpoints had met the prespecified criteria for statistical significance in favor of vemurafenib.


Options:
A: Arm Label: RCM-OSS procedure; Type: EXPERIMENTAL; Interventions: Device: Reflectance confocal microscopy, Procedure: Surgical excision | Arm Label: Standard of care procedure; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Punch biopsy, Procedure: Surgical excision | Intervention Type: DEVICE; Name: Reflectance confocal microscopy; Assigned to Arm(s): RCM-OSS procedure | Intervention Type: PROCEDURE; Name: Punch biopsy; Assigned to Arm(s): Standard of care procedure | Intervention Type: PROCEDURE; Name: Surgical excision; Assigned to Arm(s): RCM-OSS procedure, Standard of care procedure
B: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
D: Arm Label: Nevi from participants; Type: EXPERIMENTAL; Interventions: Genetic: To test the frequency of BRAF and NRAS mutations among nevi | Intervention Type: GENETIC; Name: To test the frequency of BRAF and NRAS mutations among nevi; Assigned to Arm(s): Nevi from participants

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BRIM 3: A Randomized, Open-Label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving Vemurafenib (RO5185426) or Dacarbazine
Brief Summary: This randomized, open-label study evaluated the efficacy, safety and tolerability of vemurafenib (RO5185426) as compared to dacarbazine in previously untreated patients with metastatic melanoma. Patients were randomized to receive either vemurafenib 960 mg orally twice daily or dacarbazine 1000 mg/m2 intravenously every 3 weeks. Study treatment was continued until disease progression or unacceptable toxicity occurred. The data and safety monitoring board recommended that patients in the dacarbazine group be allowed to cross over to receive vemurafenib, and the protocol was amended accordingly on January 14, 2011, as both overall survival and progression-free survival endpoints had met the prespecified criteria for statistical significance in favor of vemurafenib.


Options:
A: Arm Label: Placebo + Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Vemurafenib | Arm Label: Cobimetinib + Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Vemurafenib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Cobimetinib + Vemurafenib, Placebo + Vemurafenib | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): Cobimetinib + Vemurafenib
B: Arm Label: Single arm; Type: EXPERIMENTAL; Interventions: Drug: vemurafenib | Intervention Type: DRUG; Name: vemurafenib; Assigned to Arm(s): Single arm
C: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
D: Arm Label: Dostarlimab (TSR-042) (singly); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) (singly) | Arm Label: Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination); Type: EXPERIMENTAL; Interventions: Drug: Dostarlimab (TSR-042) and TSR-022 (combination) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) (singly); Assigned to Arm(s): Dostarlimab (TSR-042) (singly) | Intervention Type: DRUG; Name: Dostarlimab (TSR-042) and TSR-022 (combination); Assigned to Arm(s): Dostarlimab (TSR-042) and Cobolimab TSR-022 (combination)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: BRIM 3: A Randomized, Open-Label, Controlled, Multicenter, Phase III Study in Previously Untreated Patients With Unresectable Stage IIIC or Stage IV Melanoma With V600E BRAF Mutation Receiving Vemurafenib (RO5185426) or Dacarbazine
Brief Summary: This randomized, open-label study evaluated the efficacy, safety and tolerability of vemurafenib (RO5185426) as compared to dacarbazine in previously untreated patients with metastatic melanoma. Patients were randomized to receive either vemurafenib 960 mg orally twice daily or dacarbazine 1000 mg/m2 intravenously every 3 weeks. Study treatment was continued until disease progression or unacceptable toxicity occurred. The data and safety monitoring board recommended that patients in the dacarbazine group be allowed to cross over to receive vemurafenib, and the protocol was amended accordingly on January 14, 2011, as both overall survival and progression-free survival endpoints had met the prespecified criteria for statistical significance in favor of vemurafenib.


Options:
A: Arm Label: Arm A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Arm B Interferon 1 year; Type: EXPERIMENTAL; Interventions: Drug: Interferon-alpha2b - 1 year | Arm Label: Arm C Interferon 2 years; Type: EXPERIMENTAL; Interventions: Drug: Interferon-alpha2b - 2 years | Intervention Type: DRUG; Name: Interferon-alpha2b - 1 year; Assigned to Arm(s): Arm B Interferon 1 year | Intervention Type: DRUG; Name: Interferon-alpha2b - 2 years; Assigned to Arm(s): Arm C Interferon 2 years
B: Arm Label: observation; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: pegylated interferon alfa; Type: EXPERIMENTAL; Interventions: Biological: pegylated interferon alfa, Procedure: adjuvant therapy | Intervention Type: BIOLOGICAL; Name: pegylated interferon alfa; Assigned to Arm(s): pegylated interferon alfa | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): pegylated interferon alfa
C: Arm Label: WEX only; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Wide Excision | Arm Label: WEX + SLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sentinel Lymph Node Dissection | Arm Label: WEX+SLND+CLND; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Complete Lymph Node Dissection | Intervention Type: PROCEDURE; Name: Sentinel Lymph Node Dissection; Assigned to Arm(s): WEX + SLND | Intervention Type: PROCEDURE; Name: Complete Lymph Node Dissection; Assigned to Arm(s): WEX+SLND+CLND | Intervention Type: PROCEDURE; Name: Wide Excision; Assigned to Arm(s): WEX only
D: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Docosahexaenoic Acid (DHA) on Fetal Cardiac Outcomes
Brief Summary: DHA, a type of fatty acid, is important in early development, both in terms of reproductive physiology of gestation and in postnatal behavioral and cognitive function. In adults, DHA has been shown to lower triglycerides and is important to cardiovascular health and autonomic control, lowering heart rate and blood pressure and increasing heart variability. Little is known about how fatty acids impact cardiac control in infants, children or the fetus. Our hypothesis is that maternal DHA supplementation (600 mg/day) will lower fetal HR and increase fetal HRV.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA Supplements | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo Supplements | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA Supplements; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo Supplements; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 fatty acids | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Omega-3 fatty acids | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 fatty acids; Assigned to Arm(s): 1, 2
C: Arm Label: Docosahexaenoic Acid (DHA); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: DHA | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA; Assigned to Arm(s): Docosahexaenoic Acid (DHA) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: DHA supplementation; Type: EXPERIMENTAL; Interventions: Dietary Supplement: DHA Supplementation | Arm Label: Control (milk without DHA); Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Control (milk without DHA) | Intervention Type: DIETARY_SUPPLEMENT; Name: DHA Supplementation; Assigned to Arm(s): DHA supplementation | Intervention Type: DIETARY_SUPPLEMENT; Name: Control (milk without DHA); Assigned to Arm(s): Control (milk without DHA)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TDCS-enhanced Stroke Recovery and Cortical Reorganization
Brief Summary: The purpose is to determine whether application of a non-invasive battery powered device called transcranial direct current stimulation (tDCS) can improve recovery of hand weakness after stroke beyond what is achievable with rehabilitative treatment alone.


Options:
A: Arm Label: CIMT + active anodal tDCS; Type: EXPERIMENTAL; Interventions: Device: active anodal transcranial Direct Current Stimulation (tDCS), Behavioral: Constraint Induced Movement Therapy (CIMT) | Arm Label: CIMT + sham tDCS; Type: SHAM_COMPARATOR; Interventions: Device: sham transcranial Direct Current Stimulation, Behavioral: Constraint Induced Movement Therapy (CIMT) | Arm Label: Healthy control subjects; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: active anodal transcranial Direct Current Stimulation (tDCS); Assigned to Arm(s): CIMT + active anodal tDCS | Intervention Type: DEVICE; Name: sham transcranial Direct Current Stimulation; Assigned to Arm(s): CIMT + sham tDCS | Intervention Type: BEHAVIORAL; Name: Constraint Induced Movement Therapy (CIMT); Assigned to Arm(s): CIMT + active anodal tDCS, CIMT + sham tDCS
B: Arm Label: tDCS and occupational therapy; Type: EXPERIMENTAL; Interventions: Device: tDCS | Arm Label: Sham and occupational therapy; Type: SHAM_COMPARATOR; Interventions: Device: Sham tDCS | Intervention Type: DEVICE; Name: tDCS; Assigned to Arm(s): tDCS and occupational therapy | Intervention Type: DEVICE; Name: Sham tDCS; Assigned to Arm(s): Sham and occupational therapy
C: Arm Label: hemiplegic patient; Type: EXPERIMENTAL; Interventions: Device: transcranial Direct current stimulation | Arm Label: patient control; Type: SHAM_COMPARATOR; Interventions: Device: transcranial Direct current stimulation | Intervention Type: DEVICE; Name: transcranial Direct current stimulation; Assigned to Arm(s): hemiplegic patient, patient control
D: Arm Label: SHAM TDCS; Type: SHAM_COMPARATOR; Interventions: Device: Application of Transcranial direct current stimulation (TDCS) | Arm Label: True TDCS; Type: ACTIVE_COMPARATOR; Interventions: Device: Transcranial Direct current stimulation | Intervention Type: DEVICE; Name: Application of Transcranial direct current stimulation (TDCS); Assigned to Arm(s): SHAM TDCS | Intervention Type: DEVICE; Name: Transcranial Direct current stimulation; Assigned to Arm(s): True TDCS

Answer: B